Merck & Co., Inc. (MRK) EV/Assets Ratio: 2.62x
Is Merck & Co., Inc.’s EV/Assets ratio high or low?
Merck & Co., Inc.'s EV/Assets ratio of 2.62x is in line with its 5-year average of 2.53x, around the middle of its 5-year range (1.81x–3.47x).
The EV/Assets ratio for Merck & Co., Inc. (MRK) is 2.62x as of Wednesday, June 10, 2026. It is above its 12-month average by 18.57% (2.21x).
MRK EV/Assets Ratio Chart
MRK Average EV/Assets Ratio Chart
MRK Current vs Average EV/Assets Ratio Chart
MRK EV/Assets Ratio Metrics
EV/ASSETS RATIO
2.62x
EV/ASSETS RATIO AVG TTM
2.21x
EV/ASSETS RATIO AVG 3Y
2.57x
EV/ASSETS RATIO AVG 5Y
2.53x
EV/ASSETS RATIO AVG 10Y
2.39x
EV/ASSETS RATIO AVG 15Y
2.07x
EV/ASSETS RATIO AVG 20Y
1.94x
CURRENT VS TTM AVG
+18.57%
CURRENT VS 3Y AVG
+1.76%
CURRENT VS 5Y AVG
+3.49%
CURRENT VS 10Y AVG
+9.57%
CURRENT VS 15Y AVG
+26.57%
CURRENT VS 20Y AVG
+34.89%
MRK Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | — | 2.62x | 2.21x | 2.57x | 2.53x |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 1.34x | 1.11x | 1.57x | 1.80x |
| AbbVie Inc. (ABBV) | $399.54B | 3.40x | 3.28x | 2.82x | 2.56x |
| Amgen Inc. (AMGN) | $183.75B | 2.49x | 2.46x | 2.27x | 2.38x |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 1.94x | 2.16x | 2.33x | 2.57x |
| Abbott Laboratories (ABT) | $154.66B | 1.65x | 2.50x | 2.67x | 2.75x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 2.97x | 3.05x | 2.44x | 2.15x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 7.30x | 8.88x | 9.09x | 8.50x |
| Pfizer Inc. (PFE) | $146.36B | 1.01x | 1.00x | 1.03x | 1.28x |
| Danaher Corporation (DHR) | $130.25B | 1.72x | 1.98x | 2.16x | 2.26x |
Merck & Co., Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The EV/Assets ratio for MRK stock is 2.62x.
- Is Merck & Co., Inc.'s EV/Assets ratio high or low?
- Merck & Co., Inc.'s EV/Assets ratio of 2.62x is in line with its 5-year average of 2.53x, around the middle of its 5-year range (1.81x–3.47x).
- What is the TTM average EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The TTM average EV/Assets ratio for MRK stock is 2.21x.
- What is the 3Y average EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The 3Y average EV/Assets ratio for MRK stock is 2.57x.
- What is the 5Y average EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The 5Y average EV/Assets ratio for MRK stock is 2.53x.
- What is the 10Y average EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The 10Y average EV/Assets ratio for MRK stock is 2.39x.
- What is the 15Y average EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The 15Y average EV/Assets ratio for MRK stock is 2.07x.
- What is the 20Y average EV/Assets ratio for Merck & Co., Inc. (MRK)?
- The 20Y average EV/Assets ratio for MRK stock is 1.94x.
Merck & Co., Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 2.62x |
| 2026-06-09 | 2.64x |
| 2026-06-08 | 2.64x |
| 2026-06-05 | 2.66x |
| 2026-06-04 | 2.65x |
| 2026-06-03 | 2.54x |
| 2026-06-02 | 2.56x |
| 2026-06-01 | 2.55x |
| 2026-05-29 | 2.62x |
| 2026-05-28 | 2.64x |
| 2026-05-27 | 2.65x |
| 2026-05-26 | 2.64x |
| 2026-05-22 | 2.69x |
| 2026-05-21 | 2.57x |
| 2026-05-20 | 2.51x |
| 2026-05-19 | 2.53x |
| 2026-05-18 | 2.50x |
| 2026-05-15 | 2.48x |
| 2026-05-14 | 2.52x |
| 2026-05-13 | 2.52x |
| 2026-05-12 | 2.50x |
| 2026-05-11 | 2.48x |
| 2026-05-08 | 2.48x |
| 2026-05-07 | 2.50x |
| 2026-05-06 | 2.52x |
| 2026-05-05 | 2.51x |
| 2026-05-04 | 2.51x |
| 2026-05-01 | 2.30x |
| 2026-04-30 | 2.25x |
| 2026-04-29 | 2.28x |
| 2026-04-28 | 2.26x |
| 2026-04-27 | 2.27x |
| 2026-04-24 | 2.30x |
| 2026-04-23 | 2.35x |
| 2026-04-22 | 2.31x |
| 2026-04-21 | 2.31x |
| 2026-04-20 | 2.39x |
| 2026-04-17 | 2.43x |
| 2026-04-16 | 2.36x |
| 2026-04-15 | 2.41x |
| 2026-04-14 | 2.44x |
| 2026-04-13 | 2.45x |
| 2026-04-10 | 2.47x |
| 2026-04-09 | 2.49x |
| 2026-04-08 | 2.50x |
| 2026-04-07 | 2.43x |
| 2026-04-06 | 2.46x |
| 2026-04-02 | 2.46x |
| 2026-04-01 | 2.46x |
| 2026-03-31 | 2.45x |
| 2026-03-30 | 2.41x |
| 2026-03-27 | 2.44x |
| 2026-03-26 | 2.42x |
| 2026-03-25 | 2.43x |
| 2026-03-24 | 2.38x |
| 2026-03-23 | 2.37x |
| 2026-03-20 | 2.34x |
| 2026-03-19 | 2.34x |
| 2026-03-18 | 2.34x |
| 2026-03-17 | 2.37x |
| 2026-03-16 | 2.36x |
| 2026-03-13 | 2.36x |
| 2026-03-12 | 2.37x |
| 2026-03-11 | 2.38x |
| 2026-03-10 | 2.39x |
| 2026-03-09 | 2.39x |
| 2026-03-06 | 2.37x |
| 2026-03-05 | 2.37x |
| 2026-03-04 | 2.45x |
| 2026-03-03 | 2.44x |
| 2026-03-02 | 2.47x |
| 2026-02-27 | 2.51x |
| 2026-02-26 | 2.43x |
| 2026-02-25 | 2.49x |
| 2026-02-24 | 2.52x |
| 2026-02-23 | 2.57x |
| 2026-02-20 | 2.54x |
| 2026-02-19 | 2.53x |
| 2026-02-18 | 2.53x |
| 2026-02-17 | 2.52x |
| 2026-02-13 | 2.52x |
| 2026-02-12 | 2.48x |
| 2026-02-11 | 2.48x |
| 2026-02-10 | 2.44x |
| 2026-02-09 | 2.45x |
| 2026-02-06 | 2.53x |
| 2026-02-05 | 2.49x |
| 2026-02-04 | 2.46x |
| 2026-02-03 | 2.41x |
| 2026-02-02 | 2.37x |
| 2026-01-30 | 2.31x |
| 2026-01-29 | 2.27x |
| 2026-01-28 | 2.24x |
| 2026-01-27 | 2.26x |
| 2026-01-26 | 2.25x |
| 2026-01-23 | 2.27x |
| 2026-01-22 | 2.28x |
| 2026-01-21 | 2.32x |
| 2026-01-20 | 2.29x |
| 2026-01-16 | 2.28x |
| 2026-01-15 | 2.32x |
| 2026-01-14 | 2.32x |
| 2026-01-13 | 2.27x |
| 2026-01-12 | 2.28x |
| 2026-01-09 | 2.31x |
| 2026-01-08 | 2.32x |
| 2026-01-07 | 2.27x |
| 2026-01-06 | 2.28x |
| 2026-01-05 | 2.25x |
| 2026-01-02 | 2.23x |
| 2025-12-31 | 2.21x |
| 2025-12-30 | 2.22x |
| 2025-12-29 | 2.24x |
| 2025-12-26 | 2.24x |
| 2025-12-24 | 2.23x |
| 2025-12-23 | 2.20x |
| 2025-12-22 | 2.20x |
| 2025-12-19 | 2.13x |
| 2025-12-18 | 2.12x |
| 2025-12-17 | 2.09x |
| 2025-12-16 | 2.07x |
| 2025-12-15 | 2.11x |
| 2025-12-12 | 2.11x |
| 2025-12-11 | 2.09x |
| 2025-12-10 | 2.06x |
| 2025-12-09 | 2.05x |
| 2025-12-08 | 2.09x |
| 2025-12-05 | 2.10x |
| 2025-12-04 | 2.12x |
| 2025-12-03 | 2.15x |
| 2025-12-02 | 2.13x |
| 2025-12-01 | 2.14x |
| 2025-11-28 | 2.20x |
| 2025-11-26 | 2.20x |
| 2025-11-25 | 2.22x |
| 2025-11-24 | 2.12x |
| 2025-11-21 | 2.06x |
| 2025-11-20 | 2.01x |
| 2025-11-19 | 2.01x |
| 2025-11-18 | 2.04x |
| 2025-11-17 | 1.97x |
| 2025-11-14 | 1.97x |
| 2025-11-13 | 1.97x |
| 2025-11-12 | 1.94x |
| 2025-11-11 | 1.93x |
| 2025-11-10 | 1.85x |
| 2025-11-07 | 1.84x |
| 2025-11-06 | 1.83x |
| 2025-11-05 | 1.81x |
| 2025-11-04 | 2.03x |
| 2025-11-03 | 2.00x |
| 2025-10-31 | 2.07x |
| 2025-10-30 | 2.08x |
| 2025-10-29 | 2.08x |
| 2025-10-28 | 2.09x |
| 2025-10-27 | 2.11x |
| 2025-10-24 | 2.10x |
| 2025-10-23 | 2.10x |
| 2025-10-22 | 2.11x |
| 2025-10-21 | 2.11x |
| 2025-10-20 | 2.08x |
| 2025-10-17 | 2.05x |
| 2025-10-16 | 2.03x |
| 2025-10-15 | 2.03x |
| 2025-10-14 | 2.04x |
| 2025-10-13 | 2.07x |
| 2025-10-10 | 2.07x |
| 2025-10-09 | 2.10x |
| 2025-10-08 | 2.08x |
| 2025-10-07 | 2.11x |
| 2025-10-06 | 2.13x |
| 2025-10-03 | 2.14x |
| 2025-10-02 | 2.15x |
| 2025-10-01 | 2.16x |
| 2025-09-30 | 2.03x |
| 2025-09-29 | 1.91x |
| 2025-09-26 | 1.91x |
| 2025-09-25 | 1.89x |
| 2025-09-24 | 1.94x |
| 2025-09-23 | 1.94x |
| 2025-09-22 | 1.95x |
| 2025-09-19 | 1.98x |
| 2025-09-18 | 1.98x |
| 2025-09-17 | 1.97x |
| 2025-09-16 | 1.97x |
| 2025-09-15 | 1.97x |
| 2025-09-12 | 2.00x |
| 2025-09-11 | 2.05x |
| 2025-09-10 | 2.03x |
| 2025-09-09 | 2.04x |
| 2025-09-08 | 2.03x |
| 2025-09-05 | 2.04x |
| 2025-09-04 | 2.03x |
| 2025-09-03 | 2.03x |
| 2025-09-02 | 2.06x |
| 2025-08-29 | 2.03x |
| 2025-08-28 | 2.01x |
| 2025-08-27 | 2.03x |
| 2025-08-26 | 2.05x |
| 2025-08-25 | 2.06x |
| 2025-08-22 | 2.10x |
| 2025-08-21 | 2.07x |
| 2025-08-20 | 2.04x |
| 2025-08-19 | 2.05x |
| 2025-08-18 | 2.03x |
| 2025-08-15 | 2.03x |
| 2025-08-14 | 2.00x |
| 2025-08-13 | 2.00x |
| 2025-08-12 | 1.95x |
| 2025-08-11 | 1.94x |
| 2025-08-08 | 1.96x |
| 2025-08-07 | 1.95x |
| 2025-08-06 | 1.93x |
| 2025-08-05 | 1.96x |
| 2025-08-04 | 1.98x |
| 2025-08-01 | 1.97x |
| 2025-07-31 | 1.95x |
| 2025-07-30 | 2.03x |
| 2025-07-29 | 2.04x |
| 2025-07-28 | 2.08x |
| 2025-07-25 | 2.09x |
| 2025-07-24 | 2.08x |
| 2025-07-23 | 2.07x |
| 2025-07-22 | 2.02x |
| 2025-07-21 | 1.97x |
| 2025-07-18 | 1.99x |
| 2025-07-17 | 2.02x |
| 2025-07-16 | 2.04x |
| 2025-07-15 | 2.02x |
| 2025-07-14 | 2.07x |
| 2025-07-11 | 2.06x |
| 2025-07-10 | 2.07x |
| 2025-07-09 | 2.07x |
| 2025-07-08 | 2.02x |
| 2025-07-07 | 2.01x |
| 2025-07-03 | 2.01x |
| 2025-07-02 | 2.04x |
| 2025-07-01 | 2.03x |
| 2025-06-30 | 1.97x |
| 2025-06-27 | 1.97x |
| 2025-06-26 | 1.96x |
| 2025-06-25 | 1.98x |
| 2025-06-24 | 1.99x |
| 2025-06-23 | 1.99x |
| 2025-06-20 | 1.97x |
| 2025-06-18 | 1.97x |
| 2025-06-17 | 1.95x |
| 2025-06-16 | 2.01x |
| 2025-06-13 | 2.02x |
| 2025-06-12 | 2.03x |
| 2025-06-11 | 1.99x |
| 2025-06-10 | 2.02x |
| 2025-06-09 | 1.97x |
| 2025-06-06 | 1.96x |
| 2025-06-05 | 1.93x |
| 2025-06-04 | 1.95x |
| 2025-06-03 | 1.92x |
| 2025-06-02 | 1.90x |
| 2025-05-30 | 1.92x |
| 2025-05-29 | 1.91x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis